(Q35218009)

7 August 2017

1 reference

title

Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients (English)

1 reference

hospital-acquired infection

7 August 2017

main subject

gram-positive bacteria

0 references

1 reference

Klastersky J

1

1 reference

7 August 2017

publication date

1 October 2003

1 reference

7 August 2017

published in

Cancer Treatment Reviews

1 reference

7 August 2017

volume

29

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

431-440

1 reference

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Science and pragmatism in the treatment and prevention of neutropenic infection

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The changing pattern of infection in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Staphylococcus aureus bacteremia in patients with Hickman catheters

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Neutropenic infections: strategies for empirical therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Staphylococcus aureus: a well-armed pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antibiotic resistance in gram-positive bacteria: epidemiological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial susceptibility of coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The comparative efficacy and safety of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

A closer look at vancomycin, teicoplanin, and antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Quinupristin-dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Inhibition of protein synthesis by streptogramins and related antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Comparative in-vitro activity of RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Post-antibiotic effect of the new streptogramin RP 59500.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Post-antibiotic effects of RP 59500 with Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900069-0

7 January 2021

10.1016/S0305-7372(03)00069-0

Identifiers

DOI

1 reference

7 August 2017

1 reference